Drug · DIN 02230578
TWINRIX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 6, 2002; first marketed September 19, 1997.
- Drug Identification Number (DIN)
- 02230578
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Combinations J07BC20
- Class
- Human
- Record last updated
- July 30, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| HEPATITIS A VIRUS, INACTIVATED | 720 UNIT | 1 ML |
| HEPATITIS B SURFACE ANTIGEN (RECOMBINANT) | 20 MCG | 1 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 25, 2006: NOC 8234Supplement to a New Drug Submission (SNDS) · Additional manufacturing facility
- June 14, 2001: NOC 2312New Drug Submission (NDS) · Manufacturer name change
- January 23, 1997: NOC 3850New Drug Submission (NDS)